Mechanism of vasoconstriction induced by chronic inhibition of nitric oxide in rats

Hypertension

Volumn 24, Issue 3, 1994, Pages 322-328

  Bank, Norman ^a,b   Aynedjian, Hagop S ^a   Khan, Ghazali A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

muscle, smooth, vascular; nitric oxide; renal circulation; vasoconstriction

Indexed keywords

ADRENALIN; ANGIOTENSIN; ARGININE; CALCIUM CHANNEL BLOCKING AGENT; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DALTROBAN; ENDOTHELIN 1; FUROSEMIDE; INDOMETACIN; NITRIC OXIDE; PROPRANOLOL; PROSTAGLANDIN; SARALASIN; THIOBUTABARBITAL; THROMBOXANE; VERAPAMIL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL TONE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MIXTURE; GLOMERULUS FILTRATION RATE; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT; VASCULAR SMOOTH MUSCLE;

EID: 0028102009     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.24.3.322     Document Type: Article

References (41)

1. G-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol. 1991;261:F1033-F1037.
2. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992;90:278-281.
3. Salazar FJ, Pinilla JM, Lopez F, Romero JC, Quesada T. Renal effects of prolonged synthesis inhibition of endothelium-derived nitric oxide. Hypertension. 1992;20:113-117.
4. Tolins JP, Shultz PJ, Raij L. Role of endothelium-derived relaxing factor in regulation of vascular tone and remodeling. Hypertension. 1991;17:909-916.
5. Loeb AL, Longnecker DE. Inhibition of endothelium-derived relaxing factor-dependent circulatory control in intact rats. Am J Physiol. 1992;262:H1494-H1500.
6. Sigmon DH, Carretero OA, Beierwaltes WH. Plasma renin activity and the renal response to nitric oxide synthesis inhibition. J Am Soc Nephrol. 1992;3:1288-1294.
7. Dananberg J, Sider RS, Grekin RJ. Sustained hypertension induced by orally administered nitro-L-arginine. Hypertension. 1993;21:359-363.
8. Sigmon DH, Carretero OA, Beierwaltes WH. Angiotensin dependence of endothelium-mediated renal hemodynamics. Hypertension. 1992;20:643-650.
9. Baylis C, Engels K, Samsell L, Harton P. Renal effects of acute endothelial-derived relaxing factor blockade are not mediated by angiotensin II. Am J Physiol. 1993;264:F74-F78.
10. Welch WJ, Wilcox CS, Aisaka K, Gross SS, Griffith OW, Fontoura BMA, Maack T, Levi R. Nitric oxide synthesis from L-arginine modulates renal vascular resistance in isolated perfused and intact rat kidneys. J Cardiovasc Pharmacol. 1991;17(suppl 3):S165-S168.
11. Ito S, Juncos LA, Nushiro N, Johnson CS, Carretero OA. Endothelium-derived relaxing factor modulates endothelin action in afferent arterioles. Hypertension. 1991;17:1052-1056.
12. Ito S, Johnson CS, Carretero OA. Modulation of angiotensin-II-induced vasoconstriction by endothelium-derived relaxing factor in the isolated microperfused rabbit afferent arteriole. J Clin Invest. 1991;87:1656-1663.
13. De Nicola L, Blantz RC, Gabbai FB. Nitric oxide and angiotensin II. J Clin Invest. 1992;89:1248-1256.
14. Lerman A, Sandok EK, Hildebrand FL Jr, Burnett JC Jr. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Circulation. 1992;85:1894-1898.
15. Ohishi K, Carmines PK, Inscho EW, Navar LG. EDRF-angiotensin II interactions in rat juxtamedullary afferent and efferent arterioles. Am J Physiol. 1992;263:F900-F906.
16. Ohyanagi M, Nishigaki K, Faber JE. Interaction between microvascular α1- and α2-adrenoceptors and endothelium-derived relaxing factor. Circ Res. 1992;71:188-200.
17. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27-36.
18. Salom MG, Lahera V, Miranda-Guardiola F, Romero JC. Blockade of pressure natriuresis induced by inhibition of renal synthesis of nitric oxide in dogs. Am J Physiol. 1992;262:F718-F722.
19. Bank N, Aynedjian HS. Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int. 1993;43:1306-1312.
20. Snell FD, Snell CT. Nitrate. In: Colorimetric Methods of Analysis. 3rd ed. New York, NY: Van Nostrand Reinhold Co Inc; 1949: 798-799.
21. Bank N, Lahorra MAG, Aynedjian HS, Schlondorff D. Vasoregulatory hormones and the hyperfiltration of diabetes. Am J Physiol. 1988;254:F202-F209.
22. 1) receptor. Semin Nephrol. 1993;13:558-566.
23. Chatziantoniou C, Arendshorst WJ. Angiotensin receptor sites in renal vasculature of rats developing genetic hypertension. Am J Physiol. 1993;265:F853-F862.
24. Bank N, Aynedjian HS. Role of thromboxane in impaired renal vasodilatation response to acetylcholine in hypercholesterolemic rats. J Clin Invest. 1992;89:1636-1642.
25. Bank N, Lahorra MAG, Aynedjian HS. Acute effect of calcium and insulin on hyperfiltration of early diabetes. Am J Physiol. 1987;252:E13-E20.
26. Nishikibe M, Tsuchida S, Okada M, Fukuroda T, Shimamoto K, Yano M, Ishikawa K, Ikemoto F. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. 1993;52:717-724.
27. Kivlighn SD, Gabel RA, Siegl PKS. Effects of BQ-123 on renal function and acute cyclosporine-induced renal dysfunction. Kidney Int. 1994;45:131-136.
28. A receptor activation. Am J Physiol. 1993;264:R222-R226.
29. G-nitro-L-arginine as affected by blockade of pressor mechanisms mediated by the sympathetic nervous system, angiotensin, prostanoids and vasopressin. J Pharmacol Exp Ther. 1992; 261:240-245.
30. Deng A, Baylis C. Locally produced EDRF controls preglomerular resistance and ultrafiltration coefficient. Am J Physiol. 1993;264: F212-F215.
31. G-nitro-L-arginine. Am J Physiol. 1992;262:F939-F942.
32. 1-adrenoceptor blockade with prazosin (P) normalize BP in chronic endothelial derived relaxing factor (EDRF) blockade induced hypertension (EB-HT). J Am Soc Nephrol. 1992;3:551. Abstract.
33. Manning RD, Hu L, Mizelle HL, Montani J-P, Norton MW. Cardiovascular responses to long-term blockade of nitric oxide synthesis. Hypertension. 1993;22:40-48.
34. Miller WL, Redfield MM, Burnett JC Jr. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest. 1989;83:317-320.
35. Thomas CP, Simonson MS, Dunn MJ. Endothelin: receptors and transmembrane signals. News Physiol Sci. 1992;7:207-211.
36. 125I]endothelin-1, endothelin-2 and endothelin-3 in rat, pig and human kidneys. J Physiol (Lond). 1989;417:35. Abstract.
37. Martin ER, Marsden PA, Brenner BM, Ballermann BJ. Identification and characterization of endothelin binding sites in rat renal papillary and glomerular membranes. Biochem Biophys Res Commun. 1989;162:130-137.
38. King AJ, Brenner BM, Anderson S. Endothelin: a potent renal and systemic vasoconstrictor peptide. Am J Physiol. 1989;256:F1051-F1058.
39. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. J Clin Invest. 1989;83:336-342.
40. Kon V, Yoshioka T, Fogo A, Ichikawa I. Glomerular actions of endothelin in vivo. J Clin Invest. 1989;83:1762-1767.
41. Cristol J-P, Warner TD, Thiemermann C, Vane JR. Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol. 1993;108:776-779.